PIEL - ETF AI Analysis
Top Page
Pacer International Export Leaders ETF (PIEL)
PIEL, the Pacer International Export Leaders ETF, earns a solid overall rating largely because many of its biggest positions—such as Novartis, AstraZeneca, ASML, Nestlé, LVMH, and Roche—show strong financial performance, healthy profitability, and generally supportive long-term outlooks. These strengths are partly offset by some holdings facing valuation concerns or weaker technical trends, and the fund’s focus on a relatively concentrated group of large international exporters means investors are exposed to risks tied to specific global sectors and regions.
PIEL vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.14M
- Region
- Global Ex-U.S.
- Expense Ratio
- 0.49%
- Beta
- 1.24
- Issuer
- Pacer
- Inception Date
- Dec 23, 2025
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- Pacer International Export Leaders Index - Benchmark TR Net
PIEL Summary
The Pacer International Export Leaders ETF (PIEL) tracks the Pacer International Export Leaders Index and invests in large and mid-sized companies outside the U.S. that earn a big share of their sales from exports. It holds well-known global names like ASML, Samsung Electronics, Nestlé, and LVMH, spread across many countries and sectors such as technology, health care, and consumer goods. Someone might invest in PIEL to diversify beyond the U.S. and benefit from growth in international trade. A key risk is that these export-focused stocks can rise or fall sharply with global economic and currency swings.
How much will it cost me?
This ETF has an expense ratio of 0.60%, which means you’ll pay about $6 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because this fund is more specialized and rules-based in how it selects international export-focused companies.
What would affect this ETF?
This ETF could benefit if global economic growth and trade pick up, boosting demand for exports from large non-U.S. companies, especially in technology, health care, and luxury consumer brands like ASML, Novartis, and LVMH. On the negative side, it could be hurt by global recessions, trade tensions, stronger regulations on drug and tech firms, or weaker consumer spending that would pressure cyclical and export-focused businesses.
PIEL Top 10 Holdings
PIEL leans heavily on a mix of European health care and Asian tech, with ASML and Samsung acting as key engines for long‑term gains thanks to their rising, export‑driven chip businesses. Roche and Novartis give the fund a steady, defensive backbone, both climbing on solid pharma pipelines. SK hynix has been strong over the year but more mixed lately, adding some volatility to the tech tilt. On the downside, LVMH has been lagging, weighing on consumer exposure. Overall, it’s a globally diversified, ex‑U.S. play with a clear bias toward export powerhouses.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 4.99% | $57.11K | EUR 539.67B | 50.70% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 CH:NOVN | Novartis AG | 4.46% | $51.04K | CHF 244.89B | 35.30% | 80Outperform |
 KR:005930 | Samsung Electronics | 4.07% | $46.52K | KRW 1432.08T | 116.14% | ―― |
 KR:000660 | SK hynix Inc. | 4.29% | $49.10K | KRW 1033.53T | 149.65% | ―― |
 DE:SAP | SAP SE | 3.94% | $45.01K | EUR 246.65B | -6.46% | 66Neutral |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 CH:NESN | Nestlé SA | 3.51% | $40.16K | CHF 217.87B | 9.36% | 71Outperform |
 FR:MC | LVMH Moet Hennessy Louis Vuitton | 2.92% | $33.42K | EUR 190.55B | -36.57% | 78Outperform |
 AU:BHP | BHP Group Ltd | 2.83% | $32.39K | AUD 292.61B | 31.18% | 68Neutral |
PIEL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PIEL, the sentiment is Negative. The current price of 28.30 is below the 20-day moving average (MA) of 28.37, below the 50-day MA of 28.75, and above the 200-day MA of 27.69, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 47.37 is Neutral, neither overbought nor oversold. The STOCH value of 81.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PIEL.
PIEL Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| PIEL | $28.30 | $31.00(9.54% Upside) | $1.14M | 0.49% | 63Neutral |
 GIEQ | $40.99 | $48.94(19.41% Upside) | $61.89M | 0.30% | 66Neutral |
 PJIO | $57.60 | $79.20(37.50% Upside) | $59.07M | 0.54% | 64Neutral |
 AADR | $80.02 | $93.98(17.45% Upside) | $35.14M | 1.09% | 69Neutral |
 ABLG | $28.31 | ― | $13.06M | 0.54% | 61Neutral |
 VNIE | $24.46 | $28.94(18.35% Upside) | $8.65M | 0.60% | 63Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PIEL | Pacer International Export Leaders ETF | 28.30 | 2.92 | 11.52% | |
| GIEQ | Goldman Sachs Data Enhanced International Equity ETF | 40.98 | 0.49 | 1.21% | |
| PJIO | PGIM Jennison International Opportunities ETF | 57.60 | -6.29 | -9.84% | |
| AADR | AdvisorShares Dorsey Wright ADR ETF | 80.02 | -3.52 | -4.22% | |
| ABLG | Abacus Fcf International Leaders Etf | 28.31 | -2.44 | -7.93% | |
| VNIE | Vontobel International Equity Active ETF | 24.45 | -0.38 | -1.51% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.